EMBARK: treatment suspension and health-related quality of life in prostate cancer [Video]

Stephen Freedland, MD, Cedars-Sinai Medical Center, Los Angeles, CA, discusses a post hoc analysis of the impact of treatment suspension on health-related quality of life (HRQoL) in the EMBARK trial (NCT02319837) in patients with high-risk biochemically recurrent non-metastatic prostate cancer. Patients were randomized to receive various hormonal therapies for 37 weeks, after which treatment was suspended if their prostate-specific antigen (PSA) levels were less than 0.2 ng/mL. Surprisingly, upon treatment suspension global QoL did not change, but HRQoL improved significantly due to a rapid reduction in hormonal symptoms. These results indicate new therapies can delay the time to metastasis without negatively impacting patients’ QoL. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.